Published in BMJ Clin Evid on May 03, 2011
Vitamin D - a systematic literature review for the 5th edition of the Nordic Nutrition Recommendations. Food Nutr Res (2013) 1.11
The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update. Transl Respir Med (2014) 0.84
Bone diseases. Incident fractures during treatment for osteoporosis. Nat Rev Rheumatol (2013) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA (2010) 11.59
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (2010) 10.85
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Involutional osteoporosis. N Engl J Med (1986) 8.20
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 6.14
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med (2009) 5.63
Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ (2008) 5.14
Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA (2001) 5.09
Esophagitis associated with the use of alendronate. N Engl J Med (1996) 4.89
Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med (2006) 4.09
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc (1999) 3.99
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int (2008) 3.80
Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma (2008) 3.74
Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet (2002) 3.70
Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ (2006) 3.53
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 3.45
Effectiveness and economic evaluation of a nurse delivered home exercise programme to prevent falls. 1: Randomised controlled trial. BMJ (2001) 3.23
Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr (2007) 3.14
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev (2005) 3.07
The crippling consequences of fractures and their impact on quality of life. Am J Med (1997) 2.98
Trends in hip fracture rates in Canada. JAMA (2009) 2.95
Randomized controlled trial of calcium in healthy older women. Am J Med (2006) 2.78
Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ (2010) 2.67
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res (2009) 2.65
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Can health visitors prevent fractures in elderly people? BMJ (1992) 2.25
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16
Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab (2007) 2.11
Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin (2004) 2.11
Translating clinical research into practice: a randomized controlled trial of exercise and incontinence care with nursing home residents. J Am Geriatr Soc (2002) 2.11
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 2.00
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab (2006) 1.88
Effect of vitamin D(3) and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial--the OSTPRE-FPS. J Bone Miner Res (2010) 1.81
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin (2008) 1.79
The menopause. Lancet (1999) 1.77
Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc (2008) 1.70
Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab (2010) 1.68
Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev (2002) 1.62
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause (2010) 1.57
Randomized placebo-controlled trial of brisk walking in the prevention of postmenopausal osteoporosis. Age Ageing (1997) 1.52
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 1.46
Stronger back muscles reduce the incidence of vertebral fractures: a prospective 10 year follow-up of postmenopausal women. Bone (2002) 1.46
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res (2007) 1.45
An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol (2000) 1.44
Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants (2006) 1.26
Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: a systematic review of randomized controlled trials. Osteoporos Int (2009) 1.25
Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res (2006) 1.24
Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.22
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res (2004) 1.14
What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res (2009) 1.09
Variations in hip fracture hospitalization rates among different race/ethnicity groups in New York City. Ethn Dis (2004) 1.08
Effect of impact exercise on bone mineral density in elderly women with low BMD: a population-based randomized controlled 30-month intervention. Osteoporos Int (2005) 1.07
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res (2005) 1.06
Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab (1994) 1.03
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone (2004) 1.03
Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int (2005) 1.01
Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord (2009) 0.98
Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res (2009) 0.97
Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res (1998) 0.96
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone (2006) 0.94
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res (2008) 0.93
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin (2003) 0.92
A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Int J Clin Pract (2008) 0.89
Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int (2005) 0.88
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res (2002) 0.86
External hip protectors are effective for the elderly with higher-than-average risk factors for hip fractures. Osteoporos Int (2009) 0.84
Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis. J Bone Miner Metab (2006) 0.82
Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost (2008) 0.82
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther (2005) 0.78
Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ (2012) 5.63
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 3.11
Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA (2008) 2.52
The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res (2015) 2.49
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA (2004) 2.20
Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res (2003) 2.15
Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol (2002) 2.05
Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid (2002) 1.66
Fracture risk associated with use of antiepileptic drugs. Epilepsia (2004) 1.55
Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study. J Bone Miner Res (2012) 1.54
The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care (2006) 1.52
High-dose treatment with vitamin A analogues and risk of fractures. Arch Dermatol (2010) 1.50
Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens (2006) 1.48
Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol (2006) 1.46
Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int (2004) 1.43
Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab (2012) 1.42
The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res (2011) 1.42
Loci for regulation of bone mineral density in men and women identified by genome wide linkage scan: the FAMOS study. Hum Mol Genet (2005) 1.42
Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg (2003) 1.40
[Teriparatide (human recombinant 1-34 parathyroid hormone)--a new treatment regimen for severe osteoporosis]. Ugeskr Laeger (2004) 1.40
Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int (2008) 1.40
[Denosumab--a new efficient osteoporosis therapy]. Ugeskr Laeger (2011) 1.39
Hyperthyroidism, bone mineral, and fracture risk--a meta-analysis. Thyroid (2003) 1.38
Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf) (2008) 1.31
Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders--a nationwide register study. Int J Eat Disord (2002) 1.27
Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab (2011) 1.24
Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int (2007) 1.22
Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int (2009) 1.22
Hypertension is a risk factor for fractures. Calcif Tissue Int (2008) 1.19
Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med (2004) 1.18
Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ (2002) 1.17
Has mortality after a hip fracture increased? J Am Geriatr Soc (2007) 1.16
Vitamin D and calcium supplementation prevents severe falls in elderly community-dwelling women: a pragmatic population-based 3-year intervention study. Aging Clin Exp Res (2005) 1.16
Vitamin D status in Greenland is influenced by diet and ethnicity: a population-based survey in an Arctic society in transition. Br J Nutr (2012) 1.14
Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int (2008) 1.10
Increased plasma concentrations of vitamin D metabolites and vitamin D binding protein in women using hormonal contraceptives: a cross-sectional study. Nutrients (2013) 1.09
Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone (2007) 1.07
Intake of vitamin D and risk of breast cancer--a meta-analysis. J Steroid Biochem Mol Biol (2008) 1.06
PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res (2013) 1.06
Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism. Thyroid (2002) 1.05
Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. Int J Cardiol (2005) 1.04
Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ (2003) 1.03
Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res (2005) 1.03
Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res (2004) 1.03
Osteoarthritis and risk of fractures. Calcif Tissue Int (2009) 1.02
Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev (2009) 1.01
Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res (2014) 0.99
Hip fracture risk in statin users--a population-based Danish case-control study. Osteoporos Int (2004) 0.99
Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab (2014) 0.98
Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res (2006) 0.98
Determinants of plasma PTH and their implication for defining a reference interval. Clin Endocrinol (Oxf) (2011) 0.97
Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int (2004) 0.96
Fractures in patients with primary hyperparathyroidism: nationwide follow-up study of 1201 patients. World J Surg (2003) 0.96
Maxillary distraction osteogenesis in a patient with pycnodysostosis: a case report. J Oral Maxillofac Surg (2004) 0.96
Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol (2009) 0.96
Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif Tissue Int (2010) 0.95
Molecular genetic analysis of the calcium sensing receptor gene in patients clinically suspected to have familial hypocalciuric hypercalcemia: phenotypic variation and mutation spectrum in a Danish population. J Clin Endocrinol Metab (2007) 0.94
The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception (2008) 0.94
Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur J Endocrinol (2006) 0.94
Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res (2013) 0.93
Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif Tissue Int (2008) 0.93
Familial hypocalciuric hypercalcaemia: a review. Curr Opin Endocrinol Diabetes Obes (2011) 0.93
Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int (2011) 0.92
Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest (2007) 0.90
Renal stones and calcifications in patients with primary hyperparathyroidism: associations with biochemical variables. Eur J Endocrinol (2012) 0.90
A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study. J Bone Miner Res (2003) 0.90
Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur J Endocrinol (2008) 0.90
Vitamin D status and bone and connective tissue turnover in brown bears (Ursus arctos) during hibernation and the active state. PLoS One (2011) 0.90
Female premenopausal fracture risk is associated with gc phenotype. J Bone Miner Res (2004) 0.89
Correlates of falling during 24 h among elderly Danish community residents. Prev Med (2004) 0.89
Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int (2010) 0.88
Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol (2011) 0.88
Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism. Eur J Endocrinol (2002) 0.88
Anxiolytics and sedatives and risk of fractures: effects of half-life. Calcif Tissue Int (2008) 0.87
Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study. Pediatrics (2002) 0.87
Skeletal consequences of familial hypocalciuric hypercalcaemia vs. primary hyperparathyroidism. Clin Endocrinol (Oxf) (2009) 0.87
[Strongly increasing incidence of hip fractures in Denmark from 1977 to 1999]. Ugeskr Laeger (2008) 0.87
Identification of rare and frequent variants of the CASR gene by high-resolution melting. Clin Chim Acta (2011) 0.87
Cobalamin and haptocorrin in human milk and cobalamin-related variables in mother and child: a 9-mo longitudinal study. Am J Clin Nutr (2013) 0.87
Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index--a cross-sectional study. J Pediatr (2004) 0.87
Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int (2008) 0.86
Vitamin D deficiency in postmenopausal, healthy women predicts increased cardiovascular events: a 16-year follow-up study. Eur J Endocrinol (2012) 0.86
Socioeconomic aspects of fractures within universal public healthcare: a nationwide case-control study from Denmark. Scand J Public Health (2006) 0.86
Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study. J Clin Endocrinol Metab (2002) 0.85
Loss of life years after a hip fracture. Acta Orthop (2009) 0.85
Increased risk of osteoporotic fractures in patients with Cushing's syndrome. Eur J Endocrinol (2002) 0.84
Fracture risk in very young women using combined oral contraceptives. Contraception (2008) 0.84
Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. J Bone Miner Res (2012) 0.84
Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. J Bone Miner Res (2004) 0.84
Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. J Bone Miner Res (2006) 0.84
Effect of growth hormone and 17beta-oestradiol treatment on metabolism and body composition in girls with Turner syndrome. Clin Endocrinol (Oxf) (2005) 0.83
Effects of increasing age, dosage, and duration of PTH treatment on BMD increase--a meta-analysis. Calcif Tissue Int (2012) 0.83
Patients with surgically cured primary hyperparathyroidism have a reduced quality of life compared with population-based healthy sex-, age-, and season-matched controls. Eur J Endocrinol (2011) 0.82
Fracture risk is increased in patients with GH deficiency or untreated prolactinomas--a case-control study. Clin Endocrinol (Oxf) (2002) 0.82
PTH treatment in hypoparathyroidism. Curr Drug Saf (2011) 0.82